HLA
ACRS icon

Hamilton Lane Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Hamilton Lane Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-97,550
Closed -$1.42M – 79
2021
Q4 		$1.42M Buy
+97,550
New +$1.48M 0.18% 45

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Hamilton Lane Advisors's ACRS Position: Q1 2022 in Review

Hamilton Lane Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 97,550 shares — an estimated $1.42M sold.

Hamilton Lane Advisors first reported a position in ACRS in Q4 2021 and held it in 1 quarter. The position peaked at $1.42M in Q4 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Hamilton Lane Advisors reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Hamilton Lane Advisors sold 97,550 Aclaris Therapeutics shares in Q1 2022, an estimated $1.42M.
  • Hamilton Lane Advisors first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 1 quarter.
  • Hamilton Lane Advisors's Aclaris Therapeutics position peaked at $1.42M in Q4 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Hamilton Lane Advisors's 13F filing for Q1 2022, filed 4 May 2022.